Insider · CIK 0001651036

Landsittel Michael

Reports to the SEC for 2 companies · WALTHAM, MA

sec.gov

Transactions

Companies

Filings

CIK

0001651036

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-03-23	DMRADamora Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+37.3K sh	—	—	37,313
2025-07-17	Blueprint Medicines CorpA Award	Chief Financial Officer	AAward	+21.4K sh	—	—	94,277
2025-07-17	Blueprint Medicines CorpD Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−51.1K sh	—	—	43,175
2025-07-17	Blueprint Medicines CorpU Disposition from Tender	Chief Financial Officer	UDisposition from Tender	−43.2K sh	—	—	0
2025-07-17	Blueprint Medicines CorpStock Option (Right to Buy)D Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−10K sh	—	—	0
2025-07-17	Blueprint Medicines CorpStock Option (Right to Buy)D Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−26K sh	—	—	0
2025-07-17	Blueprint Medicines CorpStock Option (Right to Buy)D Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−19.5K sh	—	—	0
2025-07-17	Blueprint Medicines CorpStock Option (Right to Buy)D Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−25K sh	—	—	0
2025-07-17	Blueprint Medicines CorpStock Option (Right to Buy)D Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−26.1K sh	—	—	0
2025-07-17	Blueprint Medicines CorpStock Option (Right to Buy)D Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−25K sh	—	—	0
2025-07-17	Blueprint Medicines CorpStock Option (Right to Buy)D Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−25K sh	—	—	0
2025-07-17	Blueprint Medicines CorpStock Option (Right to Buy)D Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−25K sh	—	—	0
2025-07-17	Blueprint Medicines CorpStock Option (Right to Buy)D Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−22K sh	—	—	0
2025-03-05	Blueprint Medicines CorpS Sale	Chief Financial Officer	SSale	−5,284 sh	$88.80	−$469K	72,924
2025-03-01	Blueprint Medicines CorpA Award	Chief Financial Officer	AAward	+11K sh	—	—	78,208
2025-03-01	Blueprint Medicines CorpStock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+22K sh	—	—	22,000
2024-08-15	Blueprint Medicines CorpS Sale	Chief Financial Officer	SSale	−4,409 sh	$95.23	−$420K	67,208
2024-05-15	Blueprint Medicines CorpS Sale	Chief Financial Officer	SSale	−2,486 sh	$107.17	−$266K	72,981
2024-05-15	Blueprint Medicines CorpS Sale	Chief Financial Officer	SSale	−1,364 sh	$106.56	−$145K	71,617
2024-05-08	Blueprint Medicines CorpM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+26.4K sh	$1.87	+$49.3K	73,649
2024-05-08	Blueprint Medicines CorpM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+1,818 sh	$8.80	+$16K	75,467
2024-05-08	Blueprint Medicines CorpStock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+26.4K sh	—	—	0
2024-05-08	Blueprint Medicines CorpStock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+1,818 sh	—	—	0
2024-05-02	Blueprint Medicines CorpM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+10K sh	$36.05	+$361K	57,286
2024-05-02	Blueprint Medicines CorpS Sale	Chief Financial Officer	SSale	−10K sh	$105.00	−$1.05M	47,286
2024-05-02	Blueprint Medicines CorpStock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−10K sh	—	—	0
2024-03-28	Blueprint Medicines CorpM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+5,000 sh	$36.05	+$180K	52,286
2024-03-28	Blueprint Medicines CorpS Sale	Chief Financial Officer	SSale	−5,000 sh	$95.00	−$475K	47,286
2024-03-28	Blueprint Medicines CorpStock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−5,000 sh	—	—	10,000
2024-03-15	Blueprint Medicines CorpM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+5,000 sh	$36.05	+$180K	61,020
2024-03-15	Blueprint Medicines CorpS Sale	Chief Financial Officer	SSale	−2,675 sh	$87.10	−$233K	58,345
2024-03-15	Blueprint Medicines CorpS Sale	Chief Financial Officer	SSale	−1,413 sh	$88.27	−$125K	56,932
2024-03-15	Blueprint Medicines CorpS Sale	Chief Financial Officer	SSale	−912 sh	$88.88	−$81.1K	56,020
2024-03-15	Blueprint Medicines CorpS Sale	Chief Financial Officer	SSale	−4,629 sh	$87.09	−$403K	51,391
2024-03-15	Blueprint Medicines CorpS Sale	Chief Financial Officer	SSale	−1,638 sh	$88.08	−$144K	49,753
2024-03-15	Blueprint Medicines CorpS Sale	Chief Financial Officer	SSale	−2,467 sh	$88.94	−$219K	47,286
2024-03-15	Blueprint Medicines CorpStock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−5,000 sh	—	—	15,000
2024-03-07	Blueprint Medicines CorpS Sale	Chief Financial Officer	SSale	−5,003 sh	$90.69	−$454K	56,020
2024-03-01	Blueprint Medicines CorpA Award	Chief Financial Officer	AAward	+12.5K sh	—	—	61,023
2024-03-01	Blueprint Medicines CorpStock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+25K sh	—	—	25,000
2023-03-06	Blueprint Medicines CorpS Sale	Chief Financial Officer	SSale	−2,911 sh	$45.72	−$133K	48,619
2023-03-06	Blueprint Medicines CorpS Sale	Chief Financial Officer	SSale	−96 sh	$44.48	−$4,270.08	48,523
2023-03-01	Blueprint Medicines CorpA Award	Chief Financial Officer	AAward	+12.5K sh	—	—	51,530
2023-03-01	Blueprint Medicines CorpStock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+25K sh	—	—	25,000
2022-03-07	Blueprint Medicines CorpS Sale	Chief Financial Officer	SSale	−1,047 sh	$56.19	−$58.8K	39,030
2022-03-03	Blueprint Medicines CorpS Sale	Chief Financial Officer	SSale	−1,328 sh	$60.27	−$80K	40,077
2022-03-01	Blueprint Medicines CorpA Award	Chief Financial Officer	AAward	+12.5K sh	—	—	41,405
2022-03-01	Blueprint Medicines CorpStock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+25K sh	—	—	25,000
2021-03-04	Blueprint Medicines CorpS Sale	Chief Financial Officer	SSale	−96 sh	$88.98	−$8,542.08	30,316
2021-03-04	Blueprint Medicines CorpS Sale	Chief Financial Officer	SSale	−1,411 sh	$86.61	−$122K	28,905

Recent filings

Accepted (ET)
Mar 254
Landsittel Michael0001193125-26-124476
SEC(opens sec.gov)
Jul 214
Landsittel Michael0001104659-25-069396
SEC(opens sec.gov)
Mar 74
Landsittel Michael0001415889-25-007392
SEC(opens sec.gov)
Mar 44
Landsittel Michael0001415889-25-006603
SEC(opens sec.gov)
Aug 194
Landsittel Michael0001415889-24-021550
SEC(opens sec.gov)
May 174
Landsittel Michael0001415889-24-013469
SEC(opens sec.gov)
May 104
Landsittel Michael0001415889-24-012843
SEC(opens sec.gov)

Companies

Address

C/O DAMORA THERAPEUTICS, INC., 221 CRESCENT ST, BUILDING 23, SUITE 105

WALTHAM, MA, 02453